Physician profile
Alfonso Chavez
NPI 1356326987
$1,804.19
in general payments reported to CMS, 2019-2025
23 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $13.07 · 2021: $69.57 · 2022: $379 · 2023: $176 · 2024: $223 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,099 · Education: $7.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.42 |
| Education | $7.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $235.68 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $182.48 | 2022-2025 | |
| Amgen INC. | $173.73 | 2019-2025 | Krystexxa |
| Inspire Medical Systems, INC. | $165.24 | 2022 | |
| Aurinia Pharma U.S., INC. | $142.99 | 2022-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $121.83 | 2025 | Benlysta |
| Calliditas Therapeutics US INC. | $103.41 | 2024-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.55 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $77.02 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $75.40 | 2019-2021 | |
| Genzyme Corporation | $68.49 | 2019 | |
| Abiomed | $66.36 | 2025 | |
| Lilly USA, LLC | $53.33 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Mallinckrodt Enterprises LLC | $48.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.68 | 2023 | Gattex |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $34.59 | 2022 | |
| Chiesi USA, INC. | $25.11 | 2025 | Elfabrio |
| Abbott Laboratories | $21.65 | 2021 | |
| Horizon Therapeutics Plc | $18.98 | 2023 | Krystexxa |
| Novo Nordisk INC | $18.13 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $18.04 | 2025 | Bridion |
| Shire North American Group INC | $15.49 | 2019 | |
| Scpharmaceuticals INC. | $14.41 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfonso Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.